Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Clarity Pharmaceuticals Ltd

Market Cap 763M 529M 464M 428M 401M 750M 50.07B 5.14B 1.99B 24.57B 1.98B 1.94B 85.39B P/E 2026 *
-6.97x
P/E 2027 * -6.26x
Enterprise Value 602M 417M 366M 338M 316M 592M 39.51B 4.05B 1.57B 19.39B 1.57B 1.53B 67.38B EV / Sales 2026 *
-
EV / Sales 2027 * 767x
Free-Float
79.05%
Yield 2026 *
-
Yield 2027 * -
1 day+2.93%
1 week-4.52%
Current month-15.26%
1 month-22.14%
3 months-31.27%
6 months-37.20%
Current year-37.57%
1 week 2.01
Extreme 2.01
2.27
1 month 2.01
Extreme 2.01
2.79
Current year 2.01
Extreme 2.01
4.26
1 year 2.01
Extreme 2.01
5.87
3 years 0.68
Extreme 0.675
8.98
5 years 0.36
Extreme 0.36
8.98
10 years 0.36
Extreme 0.36
8.98
Manager TitleAgeSince
Chief Executive Officer - 2024-10-10
Chief Executive Officer - 2009-12-31
Director of Finance/CFO - 2022-04-03
Director TitleAgeSince
Chairman - 2013-10-31
Director/Board Member - 2010-09-30
Director/Board Member 72 2016-03-28
Date Insider Type Main position Quantity % Market Cap.
04-21Sell

Chief Executive Officer

360,896 0.0969%
11-27Free

Chief Executive Officer

301,906 0.0812%
11-27Free

Chairman

517,916 0.1392%
Change 5-day change 1-year change 3-year change Capi.($)
+2.93%-4.52%-0.94%+212.59% 529M
-7.01%-3.08%+54.83%+111.23% 57.55B
-0.49%+8.30%+62.88%+67.95% 47.08B
-1.47%-1.56%-13.62%-15.10% 22.92B
+3.24%+8.41%+0.78%+436.06% 22.14B
+4.17%+8.64%+27.72%-15.63% 16.33B
-0.42%+4.37%+28.05%-34.22% 15.97B
+1.68%+0.10%+14.81%+169.73% 12.9B
0.00%+10.49%+130.14%+273.89% 12.85B
+2.06%+5.03%+84.22%+123.19% 11.84B
Average +0.44%+4.14%+38.89%+132.97% 22.01B
Weighted average by Cap. -1.27%+6.21%+43.53%+115.34%

Financials

2026 *2027 *
Net sales - 933K 646K 568K 523K 490K 918K 61.24M 6.28M 2.43M 30.05M 2.43M 2.37M 104M
Net income -108M -74.7M -65.62M -60.47M -56.61M -106M -7.08B -726M -281M -3.47B -280M -274M -12.07B -122M -84.62M -74.34M -68.5M -64.12M -120M -8.02B -822M -318M -3.93B -318M -311M -13.67B
Net Debt -161M -112M -97.95M -90.26M -84.49M -158M -10.56B -1.08B -420M -5.18B -419M -410M -18.01B -47.44M -32.86M -28.87M -26.6M -24.9M -46.66M -3.11B -319M -124M -1.53B -123M -121M -5.31B
Logo Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing targeted copper theranostics based on its SAR Technology Platform. It is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.
Employees
88
Date Price Change Volume
26-06-24 A$2.110 +2.93% 5,026,958
26-06-23 A$2.050 +0.99% 5,051,652
26-06-22 A$2.030 -6.45% 3,846,887
26-06-19 A$2.170 -0.91% 1,825,502
26-06-18 A$2.190 -0.90% 1,768,642
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.050AUD
Average target price
7.128AUD
Spread / Average Target
+247.68%

Annual profits - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!